BR112018015851A2 - composto, e, medicamento. - Google Patents
composto, e, medicamento.Info
- Publication number
- BR112018015851A2 BR112018015851A2 BR112018015851-8A BR112018015851A BR112018015851A2 BR 112018015851 A2 BR112018015851 A2 BR 112018015851A2 BR 112018015851 A BR112018015851 A BR 112018015851A BR 112018015851 A2 BR112018015851 A2 BR 112018015851A2
- Authority
- BR
- Brazil
- Prior art keywords
- trpa1
- compound
- antagonist
- medicine
- prophylaxis
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 239000003814 drug Substances 0.000 title abstract 3
- 101100482465 Caenorhabditis elegans trpa-1 gene Proteins 0.000 abstract 4
- 229940123524 TRPA1 antagonist Drugs 0.000 abstract 2
- 239000005557 antagonist Substances 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000011321 prophylaxis Methods 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 238000011282 treatment Methods 0.000 abstract 2
- 229940123223 TRPA1 agonist Drugs 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
a presente invenção visa prover um novo composto que tem uma atividade de antagonista de trpa1, um medicamento que contém o composto e um agente farmacêutico aplicável à profilaxia ou tratamento de doenças associadas com antagonista de trpa1 e trpa1. este composto representado pela fórmula (i): [na fórmula, em que cada símbolo é conforme definido na descrição] ou um sal farmaceuticamente aceitável do mesmo, e um medicamento ou similar que contém o composto ou um sal farmaceuticamente aceitável do mesmo, têm atividade de antagonista de trpa1 e são aplicáveis para profilaxia ou tratamento de doenças associadas com antagonistas de trpa1 e trpa1.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2016-021358 | 2016-02-05 | ||
| JP2016021358 | 2016-02-05 | ||
| PCT/JP2017/004134 WO2017135462A1 (ja) | 2016-02-05 | 2017-02-03 | 複素環スルホンアミド誘導体及びそれを含有する医薬 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018015851A2 true BR112018015851A2 (pt) | 2018-12-26 |
Family
ID=59499709
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018015851-8A BR112018015851A2 (pt) | 2016-02-05 | 2017-02-03 | composto, e, medicamento. |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US10584116B2 (pt) |
| EP (1) | EP3412664B1 (pt) |
| JP (1) | JP6906449B2 (pt) |
| KR (1) | KR20180104150A (pt) |
| CN (1) | CN108602807B (pt) |
| AU (1) | AU2017213993B2 (pt) |
| BR (1) | BR112018015851A2 (pt) |
| CA (1) | CA3012812A1 (pt) |
| DK (1) | DK3412664T3 (pt) |
| EA (1) | EA037264B1 (pt) |
| ES (1) | ES2911416T3 (pt) |
| MA (1) | MA43978A (pt) |
| MX (1) | MX2018009458A (pt) |
| PL (1) | PL3412664T3 (pt) |
| WO (1) | WO2017135462A1 (pt) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109476640B (zh) * | 2016-07-20 | 2022-02-25 | 豪夫迈·罗氏有限公司 | 双环脯氨酸化合物 |
| FR3114235A1 (fr) | 2020-09-18 | 2022-03-25 | Université Grenoble Alpes | Inhibition du canal trpa1 astrocytaire comme nouvelle cible therapeutique neuroprotectrice dans les phases prodromales de la maladie d’alzheimer |
| IT202100015098A1 (it) | 2021-06-09 | 2022-12-09 | Flonext S R L | Composto antagonista del canale trpa1 per uso in patologie degenerative della retina |
| WO2023033097A1 (ja) * | 2021-09-02 | 2023-03-09 | Ｅａファーマ株式会社 | 複素環スルホンアミド誘導体の製造方法、およびその合成中間体 |
| WO2024099403A1 (zh) * | 2022-11-10 | 2024-05-16 | 北京普祺医药科技股份有限公司 | 一种具有软药性质的硫醚类化合物、药物组合物及其用途 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8017612B2 (en) * | 2006-04-18 | 2011-09-13 | Japan Tobacco Inc. | Piperazine compound and use thereof as a HCV polymerase inhibitor |
| WO2010141805A1 (en) * | 2009-06-05 | 2010-12-09 | Janssen Pharmaceutica Nv | Heterocyclic amides as modulators of trpa1 |
| EP2520566A1 (en) * | 2011-05-06 | 2012-11-07 | Orion Corporation | New Pharmaceutical Compounds |
| WO2013108857A1 (ja) | 2012-01-17 | 2013-07-25 | 味の素株式会社 | 複素環アミド誘導体及びそれを含有する医薬 |
| AR092684A1 (es) | 2012-09-27 | 2015-04-29 | Hoffmann La Roche | Compuestos de sulfonamida sustituidos |
| EP2937335A4 (en) * | 2012-12-18 | 2016-09-14 | Ea Pharma Co Ltd | HETEROCYCLIC AMID DERIVATIVE AND MEDICAMENT THEREWITH |
| EP2774919A1 (en) * | 2013-03-06 | 2014-09-10 | Pharmeste S.R.L. In Liquidazione | Novel sulfonamide TRPA1 receptor antagonists |
| RS58376B1 (sr) | 2013-10-11 | 2019-04-30 | Hoffmann La Roche | Supstituisana heterociklična sulfonamidna jedinjenja korisna kao modulatori trpa1 |
| EP3101015B1 (en) * | 2014-01-28 | 2019-09-18 | EA Pharma Co., Ltd. | Heterocyclic sulfonamide derivative and medicine comprising same |
| JP6700291B2 (ja) * | 2015-02-15 | 2020-05-27 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | １−（ｈｅｔ）アリールスルホニル−（ピロリジン又はピペリジン）−２−カルボキサミド誘導体、及びｔｒｐａ１拮抗薬としてのそれらの使用 |
| WO2017018495A1 (ja) * | 2015-07-29 | 2017-02-02 | Ｅａファーマ株式会社 | シクロプロパン誘導体及びそれを含有する医薬 |
-
2017
- 2017-02-03 CN CN201780009998.3A patent/CN108602807B/zh active Active
- 2017-02-03 ES ES17747613T patent/ES2911416T3/es active Active
- 2017-02-03 AU AU2017213993A patent/AU2017213993B2/en active Active
- 2017-02-03 EP EP17747613.2A patent/EP3412664B1/en active Active
- 2017-02-03 EA EA201891782A patent/EA037264B1/ru unknown
- 2017-02-03 BR BR112018015851-8A patent/BR112018015851A2/pt active Search and Examination
- 2017-02-03 JP JP2017565677A patent/JP6906449B2/ja active Active
- 2017-02-03 DK DK17747613.2T patent/DK3412664T3/da active
- 2017-02-03 MX MX2018009458A patent/MX2018009458A/es unknown
- 2017-02-03 KR KR1020187025206A patent/KR20180104150A/ko not_active Application Discontinuation
- 2017-02-03 MA MA043978A patent/MA43978A/fr unknown
- 2017-02-03 PL PL17747613T patent/PL3412664T3/pl unknown
- 2017-02-03 WO PCT/JP2017/004134 patent/WO2017135462A1/ja active Application Filing
- 2017-02-03 CA CA3012812A patent/CA3012812A1/en active Pending
-
2018
- 2018-08-03 US US16/054,077 patent/US10584116B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN108602807B (zh) | 2022-05-13 |
| AU2017213993B2 (en) | 2021-03-25 |
| AU2017213993A1 (en) | 2018-09-13 |
| JP6906449B2 (ja) | 2021-07-21 |
| EA201891782A1 (ru) | 2019-06-28 |
| WO2017135462A1 (ja) | 2017-08-10 |
| US20190023699A1 (en) | 2019-01-24 |
| ES2911416T3 (es) | 2022-05-19 |
| MA43978A (fr) | 2018-12-12 |
| EP3412664A1 (en) | 2018-12-12 |
| DK3412664T3 (da) | 2022-06-07 |
| MX2018009458A (es) | 2018-09-21 |
| CA3012812A1 (en) | 2017-08-10 |
| CN108602807A (zh) | 2018-09-28 |
| EP3412664A4 (en) | 2019-10-16 |
| JPWO2017135462A1 (ja) | 2018-12-13 |
| US10584116B2 (en) | 2020-03-10 |
| EA037264B1 (ru) | 2021-03-01 |
| KR20180104150A (ko) | 2018-09-19 |
| PL3412664T3 (pl) | 2022-06-06 |
| EP3412664B1 (en) | 2022-03-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112018015851A2 (pt) | composto, e, medicamento. | |
| BR112018005861A2 (pt) | derivados de ácido oleanólico modificado com c4 para a inibição de il-17 e outros usos | |
| BR112017023233A2 (pt) | métodos para tratamento de câncer | |
| BR112015018168A2 (pt) | inibidores de rock suaves | |
| BR112015020302A2 (pt) | derivado de pirazol | |
| BR112019016291A2 (pt) | novo composto heterocíclico, seu método de preparação e composição farmacêutica compreendendo o mesmo | |
| BR112016024472A8 (pt) | composto, medicamento, e, uso de um composto | |
| BR112015028879A8 (pt) | compostos derivados heterocíclicos, composição farmacêutica compreendendo os referidos compostos e usos dos mesmos | |
| BR112015018738A8 (pt) | compostos de tetra-hidropirrolotiazina, seus usos, e composição farmacêutica | |
| BR112017010551A2 (pt) | composto, métodos para ativação de guanilato ciclase solúvel, para tratamento de uma ou mais condições selecionadas a partir de uma doença em um paciente e para tratamento de uma doença ou condição, composição farmacêutica, uso de um composto, e, medicamento. | |
| BR112015023922A2 (pt) | composição farmacêutica compreendendo um ativador de ampk e um agente serotonérgico e métodos de uso destes | |
| MX2016013529A (es) | Derivados de amidas y sales farmaceuticamente aceptables de los mismos, método de preparación de los mismos y aplicación médica de los mismos. | |
| BR112015012693A2 (pt) | derivados de pirimidona e seu uso no tratamento, melhora ou prevenção de uma doença viral | |
| BR112015016911A2 (pt) | tiadiazol, análogos dos mesmos e métodos de tratamento de condições relacionadas à deficiência de smn | |
| BR112015016793A2 (pt) | compostos de tiazolacarboxamidas e piridinacarbo-xamida úteis como inibidores de quinase pim | |
| BR112016005270A2 (pt) | compostos de aza-piridona, composições farmacêuticas e seus usos | |
| BR112015012197A8 (pt) | usos de inibidores de cdk mtor, e combinação farmacêutica compreendendo os mesmos | |
| BR112016017317A8 (pt) | composto, antagonista de trpa1, medicamento, e, método para profilaxia e/ou tratamento de uma doença que envolve trpa1 | |
| BR112015018491A2 (pt) | triterpenoides c-19-modificados com atividade inibidora de maturação de hiv | |
| BR112015030385A2 (pt) | inibidores de pi3 delta e gama quinase seletivos duplos | |
| AR096892A1 (es) | Una combinación farmacéutica para el tratamiento del melanoma | |
| BR112015022650A8 (pt) | inibidores de quinase induzível por sal macrocíclico. | |
| BR112015019919A2 (pt) | compostos bicíclicos | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| MA39765A (fr) | Formulation pharmaceutique d'un inhibiteur de la kinase pan-raf, ses procédés de préparation, et procédés d'utilisation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] |